Back to results

FDA Issues Additional Tazverik Blood Cancer Warnings After Market Recall

via AboutLawsuits Published: May 15, 2026

Summary

Federal regulators have concluded that Tazverik blood cancer rates make the lymphoma drug a bigger risk to patients' health than its benefits, urging providers to stop its use immediately.

Read full article β†’